Another was a Phase III trial to evaluate our product for the treatment of preleukemic disease called myelodysplastic syndrome. The last involved three separate Phase II trials of our product for treating diseases characterized by respiratory distress including chronic bronchitis, COPD and cystic fibrosis. The company will seek to enroll 90 dogs with mast cell tumors through its five investigational sites. Mast cell tumors are among the most common forms of cancer in dogs. Tumors are usually located within the skin of the limbs or body and can metastasize to vital organs such as the lymph nodes, bone marrow, spleen and liver.
Current treatment involves the use of steroids, radiation and chemotherapy and surgery.
Such treatment is expensive and often fails to affect a cure. Based on pilot studies, in vitro work, and our successful completion of FDA-authorized human clinical trials, we're optimistic about the outcome of this study. Favorable results will be useful in furthering our understanding of this mechanism of action and our product addresses an important need in the veterinary market. Dr. Sauniere holds both the MD and Ph.D. degrees. While a practicing physiscian specializing in oncology, he was active in medical research and is the author of more than fifty papers and reviews.